KF vs. HQL, KTF, SAR, MIY, ASG, TWN, MHN, TPVG, MIN, and JOF
Should you be buying The Korea Fund stock or one of its competitors? The main competitors of The Korea Fund include Abrdn Life Sciences Investors (HQL), DWS Municipal Income Trust (KTF), Saratoga Investment (SAR), BlackRock MuniYield Michigan Quality Fund (MIY), Liberty All-Star Growth Fund (ASG), The Taiwan Fund (TWN), BlackRock MuniHoldings New York Quality Fund (MHN), TriplePoint Venture Growth BDC (TPVG), MFS Intermediate Income Trust (MIN), and Japan Smaller Capitalization Fund (JOF). These companies are all part of the "financial services" industry.
The Korea Fund vs.
Abrdn Life Sciences Investors (NYSE:HQL) and The Korea Fund (NYSE:KF) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
Abrdn Life Sciences Investors has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, The Korea Fund has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
32.2% of Abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 70.0% of The Korea Fund shares are owned by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are owned by insiders. Comparatively, 59.5% of The Korea Fund shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Abrdn Life Sciences Investors pays an annual dividend of $1.47 per share and has a dividend yield of 10.6%. The Korea Fund pays an annual dividend of $0.45 per share and has a dividend yield of 2.1%.
In the previous week, The Korea Fund had 1 more articles in the media than Abrdn Life Sciences Investors. MarketBeat recorded 3 mentions for The Korea Fund and 2 mentions for Abrdn Life Sciences Investors. Abrdn Life Sciences Investors' average media sentiment score of 1.75 beat The Korea Fund's score of 1.57 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the media.
Abrdn Life Sciences Investors received 12 more outperform votes than The Korea Fund when rated by MarketBeat users. Likewise, 68.35% of users gave Abrdn Life Sciences Investors an outperform vote while only 66.40% of users gave The Korea Fund an outperform vote.
Summary
Abrdn Life Sciences Investors and The Korea Fund tied by winning 4 of the 8 factors compared between the two stocks.
Get The Korea Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for KF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Korea Fund Competitors List
Related Companies and Tools
This page (NYSE:KF) was last updated on 2/22/2025 by MarketBeat.com Staff
Free KF Stock Alerts